Lastly, we assessed MedTAC's ability to degrade the hepatocyte growth factor receptor (c‐Met), a receptor involved in cancer cell proliferation, invasion and metastasis.[31] MedTACc‐Met was created by substituting the scFv(PTK7) with an scFv derived from telisotuzumab[32] to specifically target c‐Met (Figure S6c, Supporting Information). Here, PTK7 is linked to cancer.